A late-stage drug development organization specific in endocrine and oncology therapy.

Furthermore, the protection profile of AEZS-108 was relatively benign with no unexpected findings and in particular, no cardiac toxicity. Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris added, With these favourable results in refractory ovarian tumor patients, we are now looking ahead to the info of our endometrial malignancy research scheduled for the 4th quarter. Conclusion – AEZS-108 was active and well tolerated in sufferers with intensely pre-treated platinum and taxane resistant ovarian cancer; – The safety profile confirmed the dosage of 267 mg/m2; – Hematological toxicity was reversible rapidly; – Non-hematological toxicities were generally limited by lower severity; – Tolerability and CBR evaluate favourably with topotecan and liposomal doxorubicin; – Overall survival is encouraging as all sufferers treated with AEZS-108 were platinum-resistant..

Nonoperative and operative treatment plans depend on the severe nature of the symptoms and the stage of the disease. The diagnosis of posterior tibial tendon dysfunction is based on a thorough background, examination of the foot and plain radiographs. In the early phases of posterior tibial tendon dysfunction, the patient will describe an insidious onset of exhaustion and vague aching on the medial aspect of the foot and ankle, which are frustrated by activity.Nonoperative and operative treatment plans depend on the severe nature of the symptoms and the stage of the disease. The diagnosis of posterior tibial tendon dysfunction is based on a thorough background, examination of the foot and plain radiographs. In the early phases of posterior tibial tendon dysfunction, the patient will describe an insidious onset of exhaustion and vague aching on the medial aspect of the foot and ankle, which are frustrated by activity.